Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8449489 | 0.83 | KMT2A (0.56) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL12224193 | 0.82 | KMT2A (0.60) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL9906164 | 0.82 | KMT2A (0.60) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL24032604 | 0.81 | LMNA (0.50) | TSHRSMN1; SMN2 | |
| SCHEMBL10253668 | 0.80 | KMT2A (0.58) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL15759500 | 0.80 | KMT2A (0.58) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL12352042 | 0.80 | KMT2A (0.58) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| Fenpentadiol SCHEMBL48969 | 0.80 | KMT2A (0.58) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL22395252 | 0.80 | KMT2A (0.58) | KMT2AMEN1NPSR1TSHRMAPK1 | |
| SCHEMBL27957669 | 0.80 | KMT2A (0.58) | KMT2AMEN1NPSR1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005003140-A1 | 4-OXO-4,7-DIHYDROTHIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | AGOURON PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, IRF3, BRD4 | KMT2A 756/4885MEN1 3801/4885NPSR1 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.